Critical Role of ABCG2 in ALA-Photodynamic Diagnosis and Therapy of Human Brain Tumor

Advances in Cancer Research

Volumn 125, Issue , 2015, Pages 197-216

  Ishikawa, Toshihisa ^a,b   Kajimoto, Yoshinaga ^b   Inoue, Yutaka ^c   Ikegami, Yoji ^c   Kuroiwa, Toshihiko ^b  

^a NGO Personalized Medicine and Healthcare   (Japan)

^b OSAKA MEDICAL COLLEGE   (Japan)

^c MEIJI PHARMACEUTICAL UNIVERSITY   (Japan)

Author keywords

ABCG2; Brain tumor; Gliobastoma; Nrf2; Photodynamic diagnosis; Photodynamic therapy; Porphyrin

Indexed keywords

AMINOLEVULINIC ACID; BREAST CANCER RESISTANCE PROTEIN; GEFITINIB; PHOTOSENSITIZING AGENT; PORPHYRIN DERIVATIVE; PROTEIN KINASE INHIBITOR; PROTOPORPHYRIN; TRANSCRIPTION FACTOR NRF2; ABC TRANSPORTER; ABCG2 PROTEIN, HUMAN; ANTINEOPLASTIC AGENT; NFE2L2 PROTEIN, HUMAN; PORPHYRIN; QUINAZOLINE DERIVATIVE; TUMOR PROTEIN;

AGE; ARTICLE; BIOACCUMULATION; BIOSYNTHESIS; BRAIN TUMOR; CANCER CELL; FLUORESCENCE; GLIOBLASTOMA; HUMAN; LIGHT EXPOSURE; MENINGIOMA; MICROSURGERY; OXIDATIVE STRESS; PHOTODYNAMIC THERAPY; PHOTOREACTIVITY; PRIORITY JOURNAL; REGULATORY MECHANISM; SURVIVAL RATE; UPREGULATION; ANIMAL; ANTAGONISTS AND INHIBITORS; BRAIN NEOPLASMS; DIAGNOSTIC USE; GENETIC TRANSCRIPTION; GENETICS; METABOLISM; MOUSE; PHOTOCHEMOTHERAPY; PROCEDURES; TRANSPORT AT THE CELLULAR LEVEL; TREATMENT OUTCOME;

AMINOLEVULINIC ACID; ANIMALS; ANTINEOPLASTIC AGENTS; ATP-BINDING CASSETTE TRANSPORTERS; BIOLOGICAL TRANSPORT; BRAIN NEOPLASMS; HUMANS; MICE; NEOPLASM PROTEINS; NF-E2-RELATED FACTOR 2; OXIDATIVE STRESS; PHOTOCHEMOTHERAPY; PORPHYRINS; PROTEIN KINASE INHIBITORS; PROTOPORPHYRINS; QUINAZOLINES; TRANSCRIPTION, GENETIC; TREATMENT OUTCOME;

EID: 84921876188     PISSN: 0065230X     EISSN: 21625557     Source Type: Book Series    
DOI: 10.1016/bs.acr.2014.11.008     Document Type: Chapter

References (89)

1. Adachi T., Nakagawa H., Chung I., Hagiya Y., Hoshijima K., Noguchi N., et al. Nrf2-dependent and -independent induction of ABC transporters ABCC1, ABCC2, and ABCG2 in HepG2 cells under oxidative stress. Journal of Experimental Therapeutics and Oncology 2007, 6:335-348.
2. An R., Hagiya Y., Tamura A., Li S., Saito H., Tokushima D., et al. Cellular phototoxicity evoked through the inhibition of human ABC transporter ABCG2 by cyclin-dependent kinase inhibitors in vitro. Pharmaceutical Research 2009, 26:449-458.
3. Andreadi C.K., Howells L.M., Atherfold P.A., Manson M.M. Involvement of Nrf2, p38, B-Raf, and nuclear factor-kappaB, but not phosphatidylinositol 3-kinase, in induction of hemeoxygenase-1 by dietary polyphenols. Molecular Pharmacology 2006, 69:1033-1040.
4. Basseville A., Bates S.E., Figg W.D., Sparreboom A. BCRP (ABCG2). Pharmacogenomics of human drug transporters: Clinical impacts 2013, 311-349. Wiley, Hoboken, NJ. T. Ishikawa, R.B. Kim, J. König (Eds.).
5. Bloom D.A., Jaiswal A.K. Phosphorylation of Nrf2 at Ser40 by protein kinase C in response to antioxidants leads to the release of Nrf2 from INrf2, but is not required for Nrf2 stabilization/accumulation in the nucleus and transcriptional activation of antioxidant response element-mediated NAD(P)H:quinone oxidoreductase-1 gene expression. Journal of Biological Chemistry 2003, 278:44675-44682.
6. Brehmer D., Greff Z., Godl K., Blencke S., Kurtenbach A., Weber M., et al. Cellular targets of gefitinib. Cancer Research 2005, 65:379-382.
7. Busch T.M., Hahn S.M. Multidrug resistance in photodynamic therapy. Cancer Biology and Therapy 2005, 4:195-196.
8. Buytaert E., Dewaele M., Agostinis P. Molecular effectors of multiple cell death pathways initiated by photodynamic therapy. Biochimica et Biophysica Acta 2007, 1776:86-107.
9. Cullinan S.B., Diehl J.A. PERK-dependent activation of Nrf2 contributes to redox homeostasis and cell survival following endoplasmic reticulum stress. Journal of Biological Chemistry 2004, 279:20108-20117.
10. Dolmans D.E., Fukumura D., Jain R.K. Photodynamic therapy for cancer. Nature Reviews. Cancer 2003, 3:380-387.
11. Döring F., Walter J., Will J., Föcking M., Boll M., Amasheh S., et al. Delta-aminolevulinic acid transport by intestinal and renal peptide transporters and its physiological and clinical implications. Journal of Clinical Investigation 1998, 101:2761-2767.
12. Dougherty T.J., Gomer C.J., Henderson B.W., Jori G., Kessel D., Korbelik M., et al. Photodynamic therapy. Journal of the National Cancer Institute 1998, 90:889-905.
13. Dougherty T.J., Kaufman J.E., Goldfarb A., Weishaupt K.R., Boyle D., Mittelman A. Photoradiation therapy for the treatment of malignant tumors. Cancer Research 1978, 39:2628-2635.
14. Doyle L.A., Yang W., Abruzzo L.V., Krogmann T., Gao Y., Rishi A.K., et al. A multidrug resistance transporter from human MCF-7 breast cancer cells. Proceedings of the National Academy of Sciences of the United States of America 1998, 95:15665-15670.
15. Dubakiene R., Kupriene M. Scientific problems of photosensitivity. Medicina (Kaunas, Lithuania) 2006, 42:619-624.
16. Floeth F.W., Stummer W. The value of metabolic imaging in diagnosis and resection of cerebral gliomas. Nature Clinical Practice. Neurology 2005, 1:62-63.
17. Gray M.J., Lipson R., Maeck J.V., Romeyn D. Use of hematoporphyrin derivative in detection and management of cervical cancer. American Journal of Obstetrics and Gynecology 1967, 99:766-771.
18. Hagiya Y., Adachi T., Ogura S., An R., Tamura A., Nakagawa H., et al. Nrf2-dependent induction of human ABC transporter ABCG2 and hemeoxygenase-1 in HepG2 cells by photoactivation of porphyrins: Biochemical implications for cancer cell response to photodynamic therapy. Journal of Experimental Therapeutics and Oncology 2008, 7:153-167.
19. Hagiya H., Endo Y., Yonemura Y., Takahashi K., Ishizuka M., Abe F., et al. Pivotal role of peptide transporter PEPT1 and ATP-binding cassette (ABC) transporter ABCG2 in 5-aminolevulinic acid (ALA)-based phototoxicity of gastric cancer cells in vitro. Photodiagnosis and Photodynamic Therapy 2012, 9:204-214.
20. Hindmarsh J.T. The porphyrias, appropriate test selection. Clinica Chimica Acta 2003, 333:203-207.
21. Hintze K.J., Katoh Y., Igarashi K., Theil E.C. Bach1 repression of ferritin and thioredoxin reductase1 is heme-sensitive in cells and in vitro and coordinates expression with heme oxygenase1, beta-globin, and NADP(H) quinone (oxido) reductase1. Journal of Biological Chemistry 2007, 282:34365-34371.
22. Huang W.C., Chen Y.J., Li L.Y., Wei Y.L., Hsu S.C., Tsai S.L., et al. Nuclear translocation of epidermal growth factor receptor by Akt-dependent phosphorylation enhances breast cancer-resistant protein expression in gefitinib-resistant cells. Journal of Biological Chemistry 2011, 286:20558-20568.
23. Igarashi K., Sun J. The heme-Bach1 pathway in the regulation of oxidative stress response and erythroid differentiation. Antioxidants and Redox Signaling 2006, 8:107-118.
24. Inoue Y., Ikegami Y., Kajimoto Y., Kuroiwa T., Ishikawa T. Inhibition of human ABC transporter ABCG2 by gefitinib to enhance the efficacy of ALA-photodynamic therapy of brain tumor: Learning from in vitro and in vivo experiments. ALA-Porphyrin Science 2013, 1:27-35.
25. Inoue Y., Ikegami Y., Sano K., Suzuki T., Yoshida H., Nakamura Y., et al. Gefitinb enhances the antitumor activity of CPT-11 in vitro and in vivo by inhibiting ABCG2 but not ABCB1: A new clue to circumvent gastrointestinal toxicity risk. Chemotherapy 2014, 59:260-272.
26. Ishikawa T., Kajimoto Y., Sun W., Nakagawa H., Inoue Y., Ikegami Y., et al. Role of Nrf2 in cancer photodynamic therapy: Regulation of human ABC transporter ABCG2. Journal of Pharmaceutical Sciences 2013, 102:3058-3069.
27. Ishikawa T., Nakagawa H., Hagiya Y., Nonoguchi N., Miyatake S., Kuroiwa T. Key role of human ABC transporter ABCG2 in photodynamic therapy and photodynamic diagnosis. Advances in Pharmacological Science 2010, 2010, 587306 (Open access doi:10.1155/2010/587306).
28. Ishikawa T., Nakagawa H. Human ABC transporter ABCG2 in cancer chemotherapy and pharmacogenomics. Journal of Experimental Therapeutics and Oncology 2009, 8:5-24.
29. Ishikawa T., Tamura A., Saito H., Wakabayashi K., Nakagawa H. Pharmacogenomics of the human ABC transporter ABCG2: From functional evaluation to drug molecular design. Naturwissenschaften 2005, 92:451-463.
30. Itoh K., Igarashi K., Hayashi N., Nishizawa M., Yamamoto M. Cloning and characterization of a novel erythroid cell-derived CNC family transcription factor heterodimerizing with the small Maf family proteins. Molecular and Cellular Biology 1995, 15:4184-4193.
31. Jonker J.W., Buitelaar M., Wagenaar E., Van Der Valk M.A., Scheffer G.L., Scheper R.J., et al. The breast cancer resistance protein protects against a major chlorophyll-derived dietary phototoxin and protoporphyria. Proceedings of the National Academy of Sciences of the United States of America 2002, 99:15649-15654.
32. Kajimoto Y., Kuroiwa T., Miyatake S., Ichioka T., Miyashita M., Tanaka H., et al. Use of 5-aminolevulinic acid in fluorescence-guided resection of meningioma with high risk of recurrence. Case report. Journal of Neurosurgery 2007, 106:1070-1074.
33. Kang K.W., Lee S.J., Park J.W., Kim S.G. Phosphatidylinositol 3-kinase regulates nuclear translocation of NF-E2-related factor 2 through actin rearrangement in response to oxidative stress. Molecular Pharmacology 2002, 62:1001-1010.
34. Kang K.A., Lee K.H., Park J.W., Lee N.H., Na H.K., Surh Y.J., et al. Triphlorethol-A induces heme oxygenase-1 via activation of ERK and NF-E2 related factor 2 transcription factor. FEBS Letters 2007, 581:2000-2008.
35. Kennedy J.C., Pottier R.H. Endogenous protoporphyrin IX, a clinically useful photosensitizer for PDT. Journal of Photochemistry and Photobiology B: Biology 1992, 14:275-292.
36. Kitamuro T., Takahashi K., Ogawa K., Udono-Fujimori R., Takeda K., Furuyama K., et al. Bach1 functions as a hypoxia-inducible repressor for the heme oxygenase-1 gene in human cells. Journal of Biological Chemistry 2003, 278:9125-9133.
37. Kobayashi A., Kang M.I., Watai Y., Tong K.I., Shibata T., Uchida K., et al. Oxidative and electrophilic stresses activate Nrf2 through inhibition of ubiquitination activity of Keap1. Molecular and Cellular Biology 2006, 26:221-229.
38. Kobayashi M., Yamamoto M. Nrf2-Keap1 regulation of cellular defense mechanisms against electrophiles and reactive oxygen species. Advances in Enzyme Regulation 2006, 46:113-140.
39. Kocanova S., Buytaert E., Matroule J.Y., Piette J., Golab J., de Witte P., et al. Induction of heme-oxygenase 1 requires the p38MAPK and PI3K pathways and suppresses apoptotic cell death following hypericin-mediated photodynamic therapy. Apoptosis 2007, 12:731-741.
40. Krishnamurthy P., Schuetz J.D. The role of ABCG2 and ABCB6 in porphyrin metabolism and cell survival. Current Pharmaceutical Biotechnology 2011, 12:647-655.
41. Krishnamurthy P., Xie T., Schuetz J.D. The role of transporters in cellular heme and porphyrin homeostasis. Pharmacology and Therapeutics 2007, 114:345-358.
42. Latunde-Dada G.O., Simpson R.J., McKie A.T. Recent advances in mammalian haem transport. Trends in Biochemical Sciences 2006, 31:182-188.
43. Lipson R.L., Baldes E.J. The photodynamic properties of a particular hematoporphyrin derivative. Archives of Dermatology 1960, 82:508-516.
44. Lipson R.L., Baldes E.J., Gray M.J. Hematoporphyrin derivative for detection and management of cancer. Cancer 1967, 20:2255-2257.
45. Lipson R.L., Baldes E.J., Olsen A.M. Hematoporphyrin derivative: A new aid for endoscopic detection of malignant disease. Journal of Thoracic and Cardiovascular Surgery 1961, 42:623-629.
46. Lipson R.L., Baldes E.J., Olsen A.M. Further evaluation of the use of hematoporphyrin derivative as a new aid for the endoscopic detection of malignant disease. Diseases of the Chest 1964, 46:676-679.
47. Liu W., Baer M.R., Bowman M.J., Pera P., Zheng X., Morgan J., et al. The tyrosine kinase inhibitor imatinib mesylate enhances the efficacy of photodynamic therapy by inhibiting ABCG2. Clinical Cancer Research 2007, 13:2463-2470.
48. Loh C.S., Vernon D., McRobert A.J., Bedwell J., Bown S.G., Brown S.B. Endogenous porphyrin distribution induced by 5-aminolevulinic acid in the tissue layer of the gastrointestinal tract. Journal of Photochemistry and Photobiology B: Biology 1993, 20:47-54.
49. Martin D., Rojo A.I., Salinas M., Diaz R., Gallardo G., Alam J., et al. Regulation of heme oxygenase-1 expression through the phosphatidylinositol 3-kinase/Akt pathway and the Nrf2 transcription factor in response to the antioxidant phytochemical carnosol. Journal of Biological Chemistry 2004, 279:8919-8929.
50. Meyer zu Schwabedissen H.E., Grube M., Dreisbach A., Jedlitschky G., Meissner K., Linnemann K., et al. Epidermal growth factor-mediated activation of the map kinase cascade results in altered expression and function of ABCG2 (BCRP). Drug Metabolism & Disposition 2006, 34:524-533.
51. Moi P., Chan K., Asunis I., Cao A., Kan Y.W. Isolation of NF-E2-related factor 2 (Nrf2), a NF-E2-like basic leucine zipper transcriptional activator that binds to the tandem NF-E2/AP1 repeat of the beta-globin locus control region. Proceedings of the National Academy of Sciences of the United States of America 1994, 91:9926-9930.
52. Motohashi H., Yamamoto M. Nrf2-Keap1 defines a physiologically important stress response mechanism. Trends in Molecular Medicine 2004, 10:549-557.
53. Nguyen T., Sherratt P.J., Nioi P., Yang C.S., Pickett C.B. Nrf2 controls constitutive and inducible expression of ARE-driven genes through a dynamic pathway involving nucleocytoplasmic shuttling by Keap1. Journal of Biological Chemistry 2005, 280:32485-32492.
54. Norman R.A. Past and future: Porphyria and porphyrins. Skinmed 2005, 4:287-292.
55. Novotny A., Xiang J., Stummerm W., Teuscher N.S., Smith D.E., Keep R.F. Mechanisms of 5-aminolevulinic acid uptake at the choroid plexus. Journal of Neurochemistry 2000, 75:321-328.
56. Ogawa K., Sun J., Taketani S., Nakajima O., Nishitani C., Sassa S., et al. Heme mediates derepression of Maf recognition element through direct binding to transcription repressor Bach1. The EMBO Journal 2001, 20:2835-2843.
57. Oyake T., Itoh K., Motohashi H., Hayashi N., Hoshino H., Nishizawa M., et al. Bach proteins belong to a novel family of BTB-basic leucine zipper transcription factors that interact with MafK and regulate transcription through the NF-E2 site. Molecular and Cellular Biology 1996, 16:6083-6095.
58. Özvegy-Laczka C., Hegedus T., Varady G., Ujhelly O., Schuetz J.D., Varadi A., et al. High-affinity interaction of tyrosine kinase inhibitors with the ABCG2 multidrug transporter. Molecular Pharmacology 2004, 65:1485-1495.
59. Pottier R., Truscott T.G. The photochemistry of hematoporphyrin and related systems. International Journal of Radiation Biology 1986, 50:421-452.
60. Reichard J.F., Motz G.T., Puga A. Heme oxygenase-1 induction by NRF2 requires inactivation of the transcriptional repressor BACH1. Nucleic Acids Research 2007, 35:7074-7086.
61. Robey R.W., Polgar O., Deeken J., To K.W., Bates S.E. ABCG2: Determining its relevance in clinical drug resistance. Cancer Metastasis Reviews 2007, 26:39-57.
62. Robey R.W., Steadman K., Polgar O., Bates S.E. ABCG2-mediated transport of photosensitizers: Potential impact on photodynamic therapy. Cancer Biology and Therapy 2005, 4:187-194.
63. Rodriguez L., Batlle A., Di Venosa G., MacRobert A.J., Battah S., Daniel H., et al. Study of the mechanisms of uptake of 5-aminolevulinic acid derivatives by PEPT1 and PEPT2 transporters as a tool to improve photodynamic therapy of tumors. International Journal of Biochemistry and Cell Biology 2006, 38:1530-1539.
64. Saito H., Hirano H., Nakagawa H., Fukami T., Oosumi K., Murakami K., et al. A new strategy of high-speed screening and quantitative structure-activity relationship analysis to evaluate human ATP-binding cassette transporter ABCG2-drug interactions. Journal of Pharmacology and Experimental Therapeutics 2006, 317:1114-1124.
65. Sanderson D.R., Fontana R.S., Lipson R.L., Baldes E.J. Hematoporphyrin as a diagnostic tool. A preliminary report of new techniques. Cancer 1972, 30:1368-1372.
66. Schneckenburger H., König K., Kunzi-Rapp K., Westphal-Frösch C., Rück A. Time-resolved in vivo fluorescence of photosensitizing porphyrins. Journal of Photochemistry and Photobiology B: Biology 1993, 21:143-147.
67. Shan Y., Lambrecht R.W., Donohue S.E., Bonkovsky H.L. Role of Bach1 and Nrf2 in up-regulation of the heme oxygenase-1 gene by cobalt protoporphyrin. The FASEB Journal 2006, 20:2651-2653.
68. Shinoda J., Yano H., Yoshida S., Okumura A., Kaku Y., Iwata T., et al. Fluorescence-guided resection of glioblastoma multiforme by using high-dose fluorescein sodium. Technical note. Journal of Neurosurgery 2003, 99:597-603.
69. Singh A., Wu H., Zhang P., Happel C., Ma J., Biswal S. Expression of ABCG2 (BCRP) is regulated by Nrf2 in cancer cells that confers side population and chemoresistance phenotype. Molecular Cancer Therapeutics 2010, 9:2365-2376.
70. Stewart C.F., Leggas M., Schuetz J.D., Panetta J.C., Cheshire P.J., Peterson J., et al. Gefitinib enhances the antitumor activity and oral bioavailability of irinotecan in mice. Cancer Research 2004, 64:7491-7499.
71. Stummer W., Novotny A., Stepp H., Goetz C., Reulen H.J. Fluorescence-guided resection of glioblastoma multiforme by using 5-aminolevulinic acid-induced porphyrins: A prospective study in 52 consecutive patients. Journal of Neurosurgery 2000, 93:1003-1013.
72. Stummer W., Pichmeier U., Meinel T., Wiestler O.D., Zanella F., Reulen H.J., et al. Fluorescence-guided surgery with 5-aminolevulinic acid for resection of malignant glioma: A randomized controlled multicenter phase III trial. The Lancet Oncology 2006, 7:392-401.
73. Stummer W., Reulen H.J., Vovotny A., Stepp H., Tonn J.C. Fluorescence-guided resections of malignant gliomas-An overview. Acta Neurochirurgica. Supplementum 2003, 88:9-12.
74. Sun J., Brand M., Zenke Y., Tashiro S., Groudine M., Igarashi K. Heme regulates the dynamic exchange of Bach1 and NF-E2-related factors in the Maf transcription factor network. Proceedings of the National Academy of Sciences of the United States of America 2004, 101:1461-1466.
75. Sun J., Hoshino H., Takaku K., Nakajima O., Muto A., Suzuki H., et al. Hemoprotein Bach1 regulates enhancer availability of heme oxygenase-1 gene. The EMBO Journal 2002, 21:5216-5224.
76. Sun W., Kajimoto Y., Miyatake S., Ishikawa T., Kuroiwa T. Gefitinib enhances the efficacy of photodynamic therapy using 5-aminolevulinic acid in malignant brain tumor cells. Photodiagnosis and Photodynamic Therapy 2013, 10:42-50.
77. Suzuki H., Tashiro S., Hira S., Sun J., Yamazaki C., Zenke Y., et al. Heme regulates gene expression by triggering Crm1-dependent nuclear export of Bach1. The EMBO Journal 2004, 23:2544-2553.
78. Tamura A., An R., Hagiya Y., Hoshijima K., Yoshida T., Mikuriya K., et al. Drug-induced phototoxicity evoked by inhibition of human ABC transporter ABCG2: Development of in vitro high-speed screening systems. Expert Opinion on Drug Metabolism & Toxicology 2008, 4:255-272.
79. Tamura A., Onishi Y., An R., Koshiba S., Wakabayashi K., Hoshijima K., et al. In vitro evaluation of photosensitivity risk related to genetic polymorphisms of human ABC transporter ABCG2 and inhibition by drugs. Drug Metabolism and Pharmacokinetics 2007, 22:428-440.
80. Tamura A., Watanabe M., Saito H., Nakagawa H., Kamachi T., Okura I., et al. Functional validation of the genetic polymorphisms of human ATP-binding cassette (ABC) transporter ABCG2: Identification of alleles that are defective in porphyrin transport. Molecular Pharmacology 2006, 70:287-296.
81. Toyoda Y., Hagiya Y., Adachi T., Hoshijima K., Kuo M.T., Ishikawa T. MRP class of human ABC transporters: Historical background and new research directions. Xenobiotica 2008, 38:833-862.
82. Tsiftsoglou A.S., Tsamadou A.I., Papadopoulou L.C. Heme as key regulator of major mammalian cellular functions: Molecular, cellular, and pharmacological aspects. Pharmacology and Therapeutics 2006, 111:327-345.
83. Wakabayashi K., Nakagawa H., Tamura A., Koshiba S., Hoshijima K., Komada M., et al. Intramolecular disulfide bond is a critical checkpoint determining degradative fates of ABC transporter ABCG2 protein. Journal of Biological Chemistry 2007, 282:27841-27846.
84. Wakabayashi K., Tamura A., Saito H., Onishi Y., Ishikawa T. Human ABC transporter ABCG2 in xenobiotic protection and redox biology. Drug Metabolism Reviews 2006, 38:371-391.
85. Weishaupt K.R., Gomer C.J., Dougherty T.J. Identification of singlet oxygen as the cytotoxic agent in photoinactivation of murine tumors. Cancer Research 1976, 36:2326-2329.
86. Whitaker C.J., Battah S.H., Forsyth M.J., Edwards C., Boyle R.W., Matthews E.K. Photosensitization of pancreatic tumour cells by delta-aminolaevulinic acid esters. Anti-Cancer Drug Design 2000, 15:161-170.
87. Yamamoto T., Suzuki T., Kobayashi A., Wakabayashi J., Maher J., Motohashi H., et al. Physiological significance of reactive cysteine residues of Keap1 in determining Nrf2 activity. Molecular and Cellular Biology 2008, 28:2758-2770.
88. Yanase K., Tsukahara S., Asada S., Ishikawa E., Imai Y., Sugimoto Y. Gefitinib reverses breast cancer resistance protein-mediated drug resistance. Molecular Cancer Therapeutics 2004, 3:1119-1125.
89. Zenke-Kawasaki Y., Dohi Y., Katoh Y., Ikura T., Ikura M., Asahara T., et al. Heme induces ubiquitination and degradation of the transcription factor Bach1. Molecular and Cellular Biology 2007, 27:6962-6971.